Dendritic cell progenitors engineered to express extracellular-vesicle–internalizing receptors enhance cancer immunotherapy in mouse models
Ali Ghasemi; Amaia Martínez-Usatorre; Yang Liu; Hadrien Demagny; Luqing Li; Yahya Mohammadzadeh; Andreas Hurtado; Mehdi Hicham · 2025 · Nature Communications
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract (excerpt)
Cancer immunotherapy using dendritic cells (DC) pulsed ex vivo with tumour antigens is considered safe, but its clinical efficacy is generally modest. Here we engineer DC progenitors (DCP), which can replenish conventional type 1 DCs…
Excerpt shown for reference under fair use — read the full paper at the publisher.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level
Negative / Null Result ReportDamaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections
Negative / Null Result ReportEffects of Bacillus subtilis on the growth performance, digestive enzymes, immune gene expression and disease resistance of white shrimp, Litopenaeus vannamei
Negative / Null Result ReportBCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
Negative / Null Result ReportFucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease
Negative / Null Result ReportGlobal Population Structure and Evolution of Bordetella pertussis and Their Relationship with Vaccination
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1038/s41467-025-64172-w